Biopharmaceutical News and Research

RSS

Autobahn Labs collaborates with CSHL to advance science from the lab to clinic

Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory.

7 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

Scientists test antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus

Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected.

2 Jun 2021

Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology

Aptamer Group today announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda.

From Aptamer Group 28 May 2021

New tool will help identify the most promising protein molecules for drug development

A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability - a vital step in the development of new medicines - is being rolled out by scientists from the UK's University of Bath through their spin-out company, BLOC Labs.

28 May 2021

Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.

21 May 2021

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years. In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death.

From AstraZeneca 14 May 2021

ProductLife Group Enters US Market with Acquisition of Leading Regulatory Drug Development Consultancy DS InPharmatics (DSI)

ProductLife Group (PLG) has taken the next step in its evolution as a global leader in end-to-end regulatory compliance services.

From DSI, a PLG Company 30 Apr 2021

Topical therapy can help safely reduce side effect of cancer treatment

Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.

28 Apr 2021

Albumedix extends research collaboration with Cobra Biologics to optimize viral vector manufacturing

Albumedix Ltd. ('Albumedix'), an emerging leader in the enablement of advanced therapies and recognized global leader in recombinant human albumin (rHA) has today announced an extension to its research collaboration with Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company.

From Albumedix Ltd. 28 Apr 2021

Phico Therapeutics awarded up to $18.2 million USD (c.£13.2 million GBP) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials

Phico Therapeutics has been awarded a grant of up to $18.2 million USD to tackle the global rising threat of drug-resistant bacteria.

From Phico Therapeutics 19 Apr 2021

Medical EdTech specialist, Continulus forms partnership with the Australian Sepsis Network

Continulus has formed a global partnership with the highly regarded Australian Sepsis Network (ASN).

From Continulus 15 Apr 2021

Biognosys announces strategic agreement with Siemens Healthineers

Biognosys announces today that it has established a strategic agreement with Siemens Healthineers through its clinical laboratory in Berkeley, California.

From Biognosys 14 Apr 2021

Albumedix Expands Production Capacity at its Commercial-Scale Recombinant Human Albumin Manufacturing Plant and Opens New Research Facilities

Albumedix Ltd. ('Albumedix'), a recognized global leader in recombinant human albumin specializing in the enablement of advanced therapies, announces the completed expansion of the company’s commercial-scale manufacturing facility, alongside with the establishment of a new Technology Centre equipped with state-of-the-art laboratories at its UK-based campus in Nottingham.

From Albumedix Ltd. 13 Apr 2021

Brooks Instrument Makes ISO/IEC 17025 Certification Available on SLA Series Biotech Mass Flow Controllers

Brooks Instrument has made the ISO/IEC 17025 certification available as an option on its SLA Series Biotech mass flow controllers (MFC).

From Brooks Instrument 13 Apr 2021

Surgery to correct congenital heart disease linked to increased risk of adult hypertension

In a medical records study covering thousands of children, a U.S.-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function, it also may be associated with an increased risk of hypertension -- high blood pressure -- within a few months or years after surgery.

8 Apr 2021

SwiftScale Biologics: Cell-Free Synthesis of Biologics

In this interview, News-Medical talks to David Mace, CEO at SwiftScale Biologics, about the work they do in cell-free synthesis, their partnership with Sartorius and the biologics field as a whole.

From Sartorius 30 Mar 2021

Albumedix announces recombinant human albumin supply partnership with FUJIFILM Wako Pure Chemical Corporation for the Japanese, Chinese and Hong Kong markets

Albumedix Ltd. (‘Albumedix’), an enabler of advanced therapies and world leader in recombinant human albumin (rHA), announced today that they have entered into a distribution agreement with established and well recognized reagent supplier FUJIFILM Wako Pure Chemical Corporation (FUJIFILM Wako) in Japan and China including Hong Kong.

From Albumedix Ltd. 29 Mar 2021

A novel approach to oral vaccination against Covid-19

Scientists at the University of Würzburg together with a pharmaceutical company are working on a novel approach to oral vaccination against the coronavirus.

26 Mar 2021

The pressure is on to diagnose and treat chronic kidney disease

In this interview, Helen Yeh, the Vice President, Biopharmaceuticals Medical, Cardiovascular, Renal and Metablosim at AstraZeneca , talks News-Medical to about chronic kidney diseas (CKD).

From AstraZeneca 26 Mar 2021